Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: A systematic review and meta-analysis of randomized controlled trials

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Kryst, Joanna ^c   Kawalec, Paweł ^b   Pilc, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c Independent EBM Expert   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; APLAVIROC; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LERSIVIRINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; VICRIVIROC; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PEER REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; VIRUS LOAD; ADULT; HIV INFECTIONS; METABOLISM; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME;

EID: 84929297957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124279     Document Type: Article

References (75)

1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flaniqan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001; 135: 17-26. PMID: 11434728
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-1730. PMID: 9848347
3. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd. AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004; 350(18): 1850-1861. PMID: 15115831
4. Gallant J, DeJesus E, Arribas J, Pozniak A, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354: 251-260. PMID: 16421366
5. Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother. 2007; 8(6): 851-871. PMID: 17425480
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 06, 2014.
7. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308(4): 387-402. doi: 10.1001/jama.2012.7961 PMID: 22820792
8. WHO. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June 2013.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010; 8(5): 336-341. doi: 10.1016/j.ijsu.2010.02.007 PMID: 20171303
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. Cochrane Collaboration and John Wiley. 2011. Available: www.cochranehandbook.org.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1): 1-12. PMID: 8721797
12. Albert JM, Conway B, Ioannidis JP, Reichelderfer P. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med. 1998; 17(21): 2435-2462. PMID: 9819838
13. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12(13): 1619-1624. PMID: 9764780
14. Raboud JM, Rae S, Montaner JS. The Incas Avanti Study Groups. Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. J Acquir Immune Defic Syndr. 2000; 24(5): 433-439. PMID: 11035613
15. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet 2011; 378(9787): 229-237. doi: 10.1016/S0140-6736(11)60983-5 PMID: 21763935
16. Gaytán JJA, Garza ERZ, Garcia MC, Chavez SBV. Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naive patients. Med Int Mex. 2004; 20(1): 29-33.
17. Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011; 25(18): 2249-2258. doi: 10.1097/QAD.0b013e32834c4c06 PMID: 21881478
18. Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard D, Hill A, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatmentnaive, HIV-1-infected population. AIDS 2011; 25(3): 335-340. doi: 10.1097/QAD.0b013e3283416873 PMID: 21150563
19. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378(9787): 238-246. doi: 10.1016/S0140-6736(11)60936-7 PMID: 21763936
20. Núñez M, Soriano V, Martín-Carbonero L, Barrios AA, Barreiro PP, Blanco F, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 2002; 3(3): 186-194. PMID: 12032877
21. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24(1): 55-65. doi: 10.1097/QAD.0b013e32833032ed PMID: 19926964
22. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008; 9(5): 324-336. doi: 10.1310/hct0905-324 PMID: 18977721
23. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368(9553): 2125-2135. PMID: 17174704
24. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363(9417): 1253-1263. PMID: 15094269
25. Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naiveHIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr. 2013; 62(2): 171-179. doi: 10.1097/QAI.0b013e31827a2ba2. PMID: 23328090
26. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, et al. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS 2010; 24(Suppl 1): S27-S36. doi: 10.1097/01.aids.0000366080.91192.55 PMID: 20023437
27. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002264/WC500118874.pdf
28. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25(6): F7-F12. doi: 10.1097/QAD.0b013e328345766f PMID: 21412057
29. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374(9692): 796-806. doi: 10.1016/S0140-6736(09)60918-1 PMID: 19647866
30. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. J Acquir Immune Defic Syndr. 2010; 55(1): 39-48. doi: 10.1097/QAI.0b013e3181da1287 PMID: 20404738
31. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007; 46(2): 125-133. PMID: 17721395
32. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009; 52(3): 350-356. doi: 10.1097/QAI.0b013e3181b064b0 PMID: 19648823
33. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379(9835): 2439-2448. doi: 10.1016/S0140-6736(12)60917-9 PMID: 22748591
34. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versusefavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013; 63(1): 96-100. doi: 10.1097/QAI.0b013e318289545c PMID: 23392460
35. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012; 12 (2): 111-118. doi: 10.1016/S1473-3099(11)70290-0 PMID: 22018760
36. Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27(11): 1771-1778. doi: 10.1097/QAD.0b013e3283612419 PMID: 23807273
37. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369(19): 1807-1818. doi: 10.1056/NEJMoa1215541 PMID: 24195548
38. Albini L, Cesana BM, Motta D, Foca E, Gotti D, Calabresi A, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 2012; 59 (1):18-30. doi: 10.1097/QAI.0b013e31823a6124 PMID: 21992924
39. Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, et al. Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. J Acquir Immune Defic Syndr. 2006; 43(3): 284-292. PMID: 16967040
40. Cameron DW, da Silva BA, Arribas JR, Myers MA, Bellos NC, Gilmore N, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008; 198(2): 234-240. doi: 10.1086/589622 PMID: 18540803
41. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011; 154(7): 445-456. doi: 10.7326/0003-4819-154-7-201104050-00316 PMID: 21320923
42. Echeverría P, Negredo E, Carosi G, Gálvez J, Gómez JL, Ocampo A, et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res. 2010; 85(2): 403-408. doi: 10.1016/j.antiviral.2009.11.008 PMID: 19941906
43. Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S. Japanese Anti-HIV-1 QD Therapy Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. Intern Med. 2011; 50(7): 699-705. PMID: 21467701
44. Josephson F, Andersson MC, Flamholc L, Gisslén M, Hagberg L, Ormaasen V, et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. Eur J Clin Pharmacol. 2010; 66(4): 349-357. doi: 10.1007/s00228-009-0763-z PMID: 19967342
45. Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, et al. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients. AIDS Res Hum Retroviruses. 2010; 26(5): 533-540. doi: 10.1089/aid.2009.0177 PMID: 20455766
46. Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, et al. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. Scand J Infect Dis. 2013; 45: 543-551. doi: 10.3109/00365548.2012.756985 PMID: 23294034
47. Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, et al. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naive, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis. 2013; 13(1): 269. doi: 10.1186/1471-2334-13-269
48. Mallolas J, Pich J, Peñaranda M, Domingo P, Knobel H, Pedrol E, et al. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. AIDS 2008; 22(3): 377-384. doi: 10.1097/QAD.0b013e3282f3db2c PMID: 18195564
49. Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retroviruses. 2010; 26(7): 747-757. doi: 10.1089/aid.2009.0105 PMID: 20624069
50. Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Duncombe C, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010; 51(7): 855-864. doi: 10.1086/656363 PMID: 20735258
51. Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, et al. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. J Infect Dis. 2010; 202 (10):1529-1537. doi: 10.1086/656718 PMID: 20942650
52. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358(20): 2095-2106. doi: 10.1056/NEJMoa074609 PMID: 18480202
53. Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, et al. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr. 2010; 53 (5):582-588. doi: 10.1097/QAI.0b013e3181cae4a1 PMID: 20090545
54. Torti C, Quiros-Roldon E, Regazzi M, Antinori A, Patroni A, Villani P, et al. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. 2005; 10(4): 505-13. PMID: 16038476
55. Torti C, Quiros-Roldan ME, Cologni G, Nichelatti M, Ceresoli F, Pinti M, et al. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals. Curr HIV Res. 2008; 6(1):43-48. PMID: 18288974
56. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010; 201(6): 803-813. doi: 10.1086/650697 PMID: 20151839
57. Sierra-Madero J, Di Perri G, Wood R, Saag M, Frank I, Craig C, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010; 11(3): 125-132. doi: 10.1310/hct1103-125 PMID: 20736149
58. Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antivir Ther. 2008; 13(2): 297-306. PMID: 18505181
59. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008; 198(8): 1113-1122. doi: 10.1086/592052 PMID: 18783318
60. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006; 20(5): 641. PMID: 16514292
61. Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006; 2: CD004535. PMID: 16625606
62. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011; 15(8): 1803-1818. doi: 10.1007/s10461-011-9939-5 PMID: 21484283
63. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383(9936): 2222-2231. doi: 10.1016/S0140-6736(14)60084-2 PMID: 24698485
64. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in threedrug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010; 12: CD004246. doi: 10.1002/14651858.CD004246.pub3 PMID: 21154355
65. Kawalec P, Kryst J, Mikrut A, Pilc A. Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials. PLoS One 2013; 8(10): e76587. doi: 10.1371/journal.pone.0076587 PMID: 24116123
66. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis PLoS One 2013; 8(7): e68995. doi: 10.1371/journal.pone.0068995 PMID: 23894391
67. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006; 368(9546): 1503-1515. PMID: 17071284
68. Bartlett JA, Chen SS, Quinn JB. Comparative Efficacy of Nucleoside/Nicleotide Reverse Transcriptase Inhibitors in Combination with Efavirenz: Results of Systematic Overview. HIV Clin Trial. 2007; 8(4): 221-226. PMID: 17720662
69. Pulido F, Hill A, van Delft, Moecklinghoff C. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev. 2012; 14(2): 124-131. PMID: 22627608
70. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naïve patients: a systematic review. AIDS Rev. 2010; 12(2): 67-75. PMID: 20571601
71. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013; 27(9): 1403-1412. doi: 10.1097/QAD.0b013e32835f1db0 PMID: 23343913
72. Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013; 12(6): 841-846. doi: 10.1517/14740338.2013.823396 PMID: 23889591
73. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014; 161(1): 1-10. doi: 10.7326/M14-0293 PMID: 24979445
74. Smith C, Ryom L, Monforte Ad, Reiss P, Mocroft A, El-Sadr W, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014; 17(4 Suppl 3): 19512. doi: 10.7448/IAS.17.4.19512 PMID: 25394021
75. Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH, et al. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014; 17: 19214. doi: 10.7448/IAS.17.1.19214 PMID: 25192857